India, April 14 -- Clearmind Medicine Inc. (CMND) has announced that CMND-100 has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder, marking a key milestone for the company's non-hallucinogenic MEAI-based drug program.
Alcohol Use Disorder remains a major unmet medical need, with limited effective treatment options and significant impact on health, behavior, and quality of life. Clearmind is developing CMND-100 as a novel, non-hallucinogenic therapeutic designed to address this gap.
The Phase I/IIa trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in adults with moderate to severe AUD. The study us...